<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296542</url>
  </required_header>
  <id_info>
    <org_study_id>2011-BV-C</org_study_id>
    <nct_id>NCT01296542</nct_id>
  </id_info>
  <brief_title>A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery</brief_title>
  <official_title>A Comparison of Prophylactic Antibacterial Efficacy of Besivance Versus VIGAMOX Administered for Three Days and One Hour Prior to Phacoemulsification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bucci Laser Vision Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bucci Laser Vision Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare antibacterial efficacy of Besivance versus VIGAMOX for decreasing bacteria of the
      conjunctiva and lid margins in cataract patients prior to surgery after both 1 hour and 3
      days of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lid and Conjunctival cultures will be taken to measure bacterial colonization.</measure>
    <time_frame>Following 3 days of antibiotic drops topically instilled</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>VIGAMOX</arm_group_label>
    <description>Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Besivance</arm_group_label>
    <description>Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with scheduled cataract surgery, men and women, 18 years of age and older.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman 18 years of age or older.

          -  Physically capable of instilling eye drop or have an appropriate person available to
             assist in administration of eye drops 4 times a day.

          -  Scheduled for phacoemulsification with intraocular lens (IOL) implantation for the
             treatment of cataract.

          -  Meet the American Society of Anesthesiology (ASA) physical status I, II, or III and be
             medically cleared for surgery.

          -  Willing to adhere to the prohibitions and restrictions specified in this protocol.

          -  Subjects must have signed an informed consent document indicating that they understand
             the purpose of and procedures required for the study and are willing to participate in
             the study.

        Exclusion Criteria:

          -  Known allergy or contraindication to the test article(s) or their components.

          -  Presence of any abnormality or significant illness in the eye that in the
             investigator's opinion could affect the subject's health or the study parameters.

          -  Presence of an active ocular infection (bacterial, viral or fungal), or positive
             history of ocular herpetic infection.

          -  History of any significant illness that could be expected to interfere with the study
             parameters. Any condition that, in the opinion of the investigator, would compromise
             the well-being of the subject or the study.

          -  Use of disallowed therapies (systemic or topical):

               -  Fluoroquinolone anti-infective agents (systemic or topical) within 1 week of
                  Visit 1 or anytime after Visit 1 for the duration of the study.

          -  Use of contact lenses for one week prior to the study and for the duration of the
             study.

          -  Received an experimental drug or used an experimental medical device within 21 days
             before the planned start of treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank A. Bucci, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bucci Laser Vision Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth Evans, C.O.T.</last_name>
    <phone>570-825-5949</phone>
    <email>Ruth@buccivision.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Michalek</last_name>
    <phone>570-825-5949</phone>
    <email>Barb@buccivision.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bucci Laser Vision Institute</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Evans</last_name>
      <phone>570-825-5949</phone>
      <email>Ruth@buccivision.com</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Michalek</last_name>
      <phone>570-825-5949</phone>
      <email>Barb@buccivision.com</email>
    </contact_backup>
    <investigator>
      <last_name>Frank A. Bucci, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <last_update_submitted>July 11, 2011</last_update_submitted>
  <last_update_submitted_qc>July 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Frank A. Bucci, Jr., MD</name_title>
    <organization>Bucci Laser Vision Institute</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 23, 2013</submitted>
    <returned>February 26, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

